This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Jw Pharmaceutical Corporation. Active years: 2014.
Company Filing History:
Years Active: 2014
Title: Kang Ryu - Innovator in Protein-Based Medicines
Introduction
Kang Ryu is a notable inventor based in Incheon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of protein-based medicines. His innovative work focuses on enhancing the efficacy of treatments for liver diseases associated with viral infections.
Latest Patents
Kang Ryu holds a patent for an interferon-α (IFN-α) fused protein that comprises IFN-α and a cytoplasmic transduction peptide (CTP). This invention is designed to improve the translocation of the fused protein into liver tissue, thereby enhancing its antiviral activity. The patent outlines a method for genetically fusing a CTP to human IFN-α, which facilitates better binding to cell membranes and improves the delivery of therapeutic agents to the liver. This advancement holds promise for developing effective treatments for various liver diseases at lower doses.
Career Highlights
Kang Ryu is associated with Jw Pharmaceutical Corporation, where he continues to work on innovative solutions in the pharmaceutical industry. His research and development efforts are aimed at creating effective therapies that can significantly impact patient care.
Collaborations
Kang Ryu collaborates with talented colleagues, including Chan Kyu Lee and Seonyoung Yang, to further advance their research initiatives. Their combined expertise contributes to the success of their projects and the development of new therapeutic options.
Conclusion
Kang Ryu's contributions to the field of biotechnology, particularly through his patented innovations, highlight his role as a key inventor in developing protein-based medicines. His work has the potential to transform treatment approaches for liver diseases, showcasing the importance of innovation in healthcare.